Nisa Investment AdvisorsはCidaraの持分を大幅に増やしましたが、赤字を出し、COOは株式を売却しました。 Nisa Investment Advisors vastly increased its Cidara stake, but the company lost money and its COO sold shares.

Nisa Investment Advisors LLCは第3四半期にCidara Therapeuticsの株式を4,898.5%増額し,646,000ドルの価値の6,748株を所有し,KLP Kapitalforvaltning ASは2,500株を追加しました. Nisa Investment Advisors LLC boosted its stake in Cidara Therapeutics by 4,898.5% in Q3, owning 6,748 shares worth $646,000, while KLP Kapitalforvaltning AS added 2,500 shares. 会社は,予想を下回った,四半期損失を1.43ドル/株と報告した. The company reported a quarterly loss of $1.43 per share, below expectations. COO・シェーン・ウォードは12月10日,9,909株を2億9,000万ドル(290億円)を販売し,同社は28.46%を削減した. COO Shane Ward sold 9,959 shares on December 10, netting $2.19 million and reducing his stake by 28.46%. シダラは,試験の最終段階にある抗真菌レザファンギンを開発しており,市場規模は69億6000万ドルで,156.11ドルの目標値でコンセンサス"ホールド"の評価を得ています. Cidara, developing the antifungal rezafungin in late-stage trials, has a market cap of $6.96 billion and a consensus "Hold" rating with a $156.11 target. 会社の投資家は,株の35.82%を保有し,内部の3.89%を保有している. Institutional investors hold 35.82% of shares, insiders 3.89%.